Tnf-alpha immunoconjugate therapy for the treatment of brain tumors
AssigneePhilogen S.P.A.
InventorTheresa Hemmerle
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNFα) immunoconjugate.
Claims20
A method of treating a brain tumor in a patient, comprising administering a TNFα immunoconjugate, the method comprising administering the TNFα immunoconjugate in combination with chemotherapy and radiotherapy to the patient, wherein the TNFα immunoconjugate comprises TNFα linked to an antibody molecule comprising L19 complementarity determining regions (CDRs), wherein the L19 CDRs are:
- VH CDR1
- SEQ ID NO:
- 1
- SFSMS
- VH CDR 2
- SEQ ID NO:
- 2
- SISGSSGTTYYADSVKG
- VH CDR 3
- SEQ ID NO:
- 3
- PFPYFDY
- VL CDR 1
- SEQ ID NO:
- 4
- RASQSVSSSFLA
- VL CDR 2
- SEQ ID NO:
- 5
- YASSRAT,
- and
- VL CDR 3
- SEQ ID NO:
- 6
- QQTGRIPPT;
- wherein the chemotherapy is temozolomide (TMZ), and wherein the brain tumor is a glioma.
(canceled)
-14. (canceled)
-22. (canceled)
-26. (canceled)
A method of treating a glioma in a patient, comprising administering a TNFα immunoconjugate in combination with chemotherapy and radiotherapy to the patient, wherein the TNFα immunoconjugate comprises TNFα linked to an antibody molecule comprising L19 complementarity determining regions (CDRs), wherein the L19 CDRs are:
- VH CDR1
- SEQ ID NO:
- 1
- SFSMS
- VH CDR 2
- SEQ ID NO:
- 2
- SISGSSGTTYYADSVKG
- VH CDR 3
- SEQ ID NO:
- 3
- PFPYFDY
- VL CDR 1
- SEQ ID NO:
- 4
- RASQSVSSSFLA
- VL CDR 2
- SEQ ID NO:
- 5
- YASSRAT,
- and
- VL CDR 3
- SEQ ID NO:
- 6
- QQTGRIPPT;
- wherein the chemotherapy is temozolomide (TMZ);
- wherein the antibody molecule comprises the L19 VH domain SEQ ID NO:
- 7 and the L19 VL domain SEQ ID NO:
- 9;
- wherein the TNFα immunoconjugate comprises TNFα linked to L19 (scFv) as set forth in SEQ ID NO:
- 10 and
- the TNFα immunoconjugate has an amino acid sequence of SEQ ID NO:
- 13.
Dependencies are inferred from the claim text.